期刊论文

Liu, Hui-Yu;Fang, De-yu;Liao, DF

英文

Biomedicine & Pharmacotherapy

0753-3322

2019

109

1276-1286

10.1016/j.biopha.2018.10.074

This research was supported, in part, by the Technological Innovation Fund for Technology-based Small and Medium-sized Enterprises from the Ministry of Science and Technology of China and by the Science and Technology Bureau of Nanjing City (#12C26213202441 and #2011cj017 to H.Y. Liu). Research was also supported by grants from the National Natural Science Foundation of China (#81173047 and #31371161 to D.F. Liao), the Construct Program of the Pharmaceutical Science Key Discipline in Hunan Province, and the Hunan Provincial Education Department (#14C0992 to J. Wang).

本校为第一机构

Type 2 diabetes mellitus (T2DM) is a chronic degenerative endocrine and metabolic disease with high mortality and morbidity, yet lacks effective therapeutics. We recently generated a novel fusion peptide INSR-IgG4Fc, Yiminsu (YMS), to facilitate the high-affinity binding and transportation of insulin. Thus, the aim of the present study was to determine whether the novel recombinant peptide, YMS, could contribute to restoring insulin sensitivity and glycaemic control in insulin resistance models and revealing its underlying mechanism. Palmitic acid (PA)-treated LO2 cells and high fat diet (HFD)...